Literature DB >> 18395712

Depletion of serotonin decreases the effects of the kappa-opioid receptor agonist U-69593 on cocaine-stimulated activity.

Elena Zakharova1, Stephanie L Collins, Maria Aberg, Adarsh Kumar, J B Fernandez, Sari Izenwasser.   

Abstract

Treatment with a kappa-opioid receptor agonist for 5 days decreases locomotor activity and reduces activity in response to a cocaine challenge 3 days later. In addition, chronic cocaine increases kappa-opioid receptor density, striatal dynorphin, and dynorphin gene expression in the striatum. The upregulation of kappa-opioid receptors after cocaine treatment occurs predominantly in brain regions that are highly innervated by serotonin. To determine if serotonin plays a role in the effects of kappa-opioid receptor agonists on cocaine-stimulated activity, parachloroamphetamine (PCA), which depleted serotonin by 53%-66%, or saline, was given prior to a five-day treatment with U-69593 or vehicle. Three days later each rat received a single injection of cocaine and locomotor activity was measured. Treatment with PCA had no effect on the ability of U-69593 alone to decrease locomotor activity. Thus, the behavioral effects of U-69593 alone were not dependent upon serotonin. In rats pretreated with saline, U-69593 treatment significantly blocked the locomotor-activating effects of cocaine. Following PCA pretreatment, however, there were no significant differences in locomotor activity in rats challenged with an injection of cocaine after treatment with U-69593 or vehicle. Thus, serotonin depletion prevented the long-lasting blockade of the locomotor-activating effects of cocaine subsequent to repeated administration of U-69593 but did not alter the effects of cocaine in rats that were treated with vehicle. Thus, the effects of PCA on U-69593 are not due to non-specific alterations in cocaine-induced locomotor activity. These findings suggest that serotonin plays an important role in mediating the effects of kappa-opioid receptor agonists on the behavioral response to cocaine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395712      PMCID: PMC2435175          DOI: 10.1016/j.ejphar.2008.02.065

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  43 in total

Review 1.  Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence.

Authors:  Ko Hasebe; Koji Kawai; Tomohiko Suzuki; Kuniaki Kawamura; Toshiaki Tanaka; Minoru Narita; Hiroshi Nagase; Tsutomu Suzuki
Journal:  Ann N Y Acad Sci       Date:  2004-10       Impact factor: 5.691

2.  Studies on the mechanism of p-chloroamphetamine neurotoxicity.

Authors:  J E Sprague; M P Johnson; C J Schmidt; D E Nichols
Journal:  Biochem Pharmacol       Date:  1996-10-25       Impact factor: 5.858

3.  The human neostriatum shows compartmentalization of neuropeptide gene expression in dorsal and ventral regions: an in situ hybridization histochemical analysis.

Authors:  Y L Hurd; M Herkenham
Journal:  Neuroscience       Date:  1995-02       Impact factor: 3.590

4.  Distinct effects of methamphetamine and cocaine on preprodynorphin messenger RNA in rat striatal patch and matrix.

Authors:  David H Adams; Glen R Hanson; Kristen A Keefe
Journal:  J Neurochem       Date:  2003-01       Impact factor: 5.372

5.  Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine.

Authors:  A C Thompson; A Zapata; J B Justice; R A Vaughan; L G Sharpe; T S Shippenberg
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

6.  Long-term effects of p-chloroamphetamine and related drugs on central serotonergic mechanisms.

Authors:  E Sanders-Bush; J A Bushing; F Sulser
Journal:  J Pharmacol Exp Ther       Date:  1975-01       Impact factor: 4.030

7.  The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat.

Authors:  C A Heidbreder; S R Goldberg; T S Shippenberg
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

8.  Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum.

Authors:  J B Daunais; D C Roberts; J F McGinty
Journal:  Neuroreport       Date:  1993-05       Impact factor: 1.837

9.  Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex.

Authors:  Elyssa B Margolis; Hagar Lock; Vladimir I Chefer; Toni S Shippenberg; Gregory O Hjelmstad; Howard L Fields
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

10.  Changes in striatal cholinergic, gabaergic, dopaminergic and serotoninergic biochemical markers after kainic acid-induced thalamic lesions in the rat.

Authors:  D Samuel; L Kerkerian-Le Goff; U Kumar; M Errami; E Scarfone; A Nieoullon
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1990
View more
  3 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 2.  Dynorphin, stress, and depression.

Authors:  Allison T Knoll; William A Carlezon
Journal:  Brain Res       Date:  2009-09-24       Impact factor: 3.252

Review 3.  Kappa Opioid Receptor Mediated Differential Regulation of Serotonin and Dopamine Transporters in Mood and Substance Use Disorder.

Authors:  Durairaj Ragu Varman; Lankupalle D Jayanthi; Sammanda Ramamoorthy
Journal:  Handb Exp Pharmacol       Date:  2022
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.